<DOC>
	<DOC>NCT00189579</DOC>
	<brief_summary>The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.</brief_summary>
	<brief_title>Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>18 years or older; patients with histologically proven diagnosis of ovarian cancer. Patients with metastatic disease and an overexpression of HER2 (as determined by immunochemistry) Patients who have progressed while receiving treatment, or within 6 months after completion of treatment. Patients must have received carboplatin and paclitaxel. Patients who have received at minimum one line of chemotherapy 3 weeks minimum since last treatment with chemotherapy must have elapsed Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 &gt; 1.25 x upper limit of normal (ULN) Patients must have ECOG of 2 or less Left ventricular ejection fraction (LVEF) of 50% or better Patients have given their signed and verbal consent Previous treatment with Herceptin or similar products affected growth factors (eg: Iressa) Another experimental treatment in the previous 30 days No overexpression of HER2 receptors Patients having received highdose chemotherapy or stemcell interventions Other cancers within the last 5 years Patients with dyspnea at rest or requiring oxygen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HERCEPTIN</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Relapse</keyword>
</DOC>